Oct-01 -

Soft Tissue & Bone

EORTC 62001 – Dose finding and phase II study of STI 571 in advanced soft tissue sarcoma.

This EORTC trial is one of the landmark studies of the organization, whereby the EORTC Soft Tissue and Bone Sarcoma Group (STBG) helped develop imatinib as a treatment for metastatic gastrointestinal stromal tumours (GISTs) by identifying safe dosage and studying early activity of the drug. This remains the reference treatment for this disease.


Go to Top